SQZ Biotechnologies Company (SQZB)
SQZB Stock Price Chart
Explore SQZ Biotechnologies Company interactive price chart. Choose custom timeframes to analyze SQZB price movements and trends.
SQZB Company Profile
Discover essential business fundamentals and corporate details for SQZ Biotechnologies Company (SQZB) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
30 Oct 2020
Employees
53.00
Website
https://www.sqzbiotech.comCEO
Lawrence J. Knopf
Description
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
SQZB Financial Timeline
Browse a chronological timeline of SQZ Biotechnologies Company corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 4 Jun 2025
Earnings released on 29 May 2025
Earnings released on 28 Mar 2025
Earnings released on 18 Nov 2024
Earnings released on 24 Sept 2024
Earnings released on 13 Jun 2024
Earnings released on 29 Feb 2024
Earnings released on 8 Nov 2023
EPS came in at -$0.54 surpassing the estimated -$0.66 by +18.18%.
Earnings released on 10 Aug 2023
EPS came in at -$0.57 surpassing the estimated -$0.60 by +5.00%, while revenue for the quarter reached $178.00K , missing expectations by -94.38%.
Stock split effective on 7 Jul 2023
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 10 May 2023
EPS came in at -$0.60 falling short of the estimated -$0.51 by -17.94%.
Earnings released on 22 Mar 2023
EPS came in at -$0.46 surpassing the estimated -$0.80 by +42.76%, while revenue for the quarter reached $11.94M , beating expectations by +132.90%.
Earnings released on 29 Sept 2022
EPS came in at -$0.77 surpassing the estimated -$0.82 by +5.70%, while revenue for the quarter reached $3.45M , missing expectations by -18.91%.
Earnings released on 29 Jun 2022
EPS came in at -$0.78 falling short of the estimated -$0.76 by -3.04%, while revenue for the quarter reached $3.22M , missing expectations by -17.81%.
Earnings released on 30 Mar 2022
EPS came in at -$0.75 , while revenue for the quarter reached $2.87M .
Earnings released on 30 Dec 2021
EPS came in at -$0.42 surpassing the estimated -$0.69 by +38.66%, while revenue for the quarter reached $12.35M , beating expectations by +150.80%.
Earnings released on 29 Sept 2021
EPS came in at -$0.80 , while revenue for the quarter reached $4.76M .
SQZB Stock Performance
Access detailed SQZB performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.